These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Kaji H; Kanatani M; Sugimoto T; Chihara K Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780 [TBL] [Abstract][Full Text] [Related]
4. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996 [TBL] [Abstract][Full Text] [Related]
5. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644 [TBL] [Abstract][Full Text] [Related]
6. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation. Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673 [TBL] [Abstract][Full Text] [Related]
7. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity. Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309 [TBL] [Abstract][Full Text] [Related]
8. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. Kondo H; Guo J; Bringhurst FR J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438 [TBL] [Abstract][Full Text] [Related]
10. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054 [TBL] [Abstract][Full Text] [Related]
11. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398 [TBL] [Abstract][Full Text] [Related]
12. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. Valverde P; Tu Q; Chen J J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638 [TBL] [Abstract][Full Text] [Related]
13. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755 [TBL] [Abstract][Full Text] [Related]
14. Regulation of osteoclastogenesis by gap junction communication. Matemba SF; Lie A; Ransjö M J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710 [TBL] [Abstract][Full Text] [Related]
15. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985 [TBL] [Abstract][Full Text] [Related]
16. Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis. Amcheslavsky A; Hemmi H; Akira S; Bar-Shavit Z J Bone Miner Res; 2005 Sep; 20(9):1692-9. PubMed ID: 16059640 [TBL] [Abstract][Full Text] [Related]
17. Serotonin regulates osteoclast differentiation through its transporter. Battaglino R; Fu J; Späte U; Ersoy U; Joe M; Sedaghat L; Stashenko P J Bone Miner Res; 2004 Sep; 19(9):1420-31. PubMed ID: 15312242 [TBL] [Abstract][Full Text] [Related]
18. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. Mukohyama H; Ransjö M; Taniguchi H; Ohyama T; Lerner UH Biochem Biophys Res Commun; 2000 Apr; 271(1):158-63. PubMed ID: 10777696 [TBL] [Abstract][Full Text] [Related]
19. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085 [TBL] [Abstract][Full Text] [Related]
20. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. Yu X; Huang Y; Collin-Osdoby P; Osdoby P J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]